Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
CDXS's Cash to Debt is ranked higher than
84% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. CDXS: No Debt )
CDXS' s 10-Year Cash to Debt Range
Min: 2.78   Max: No Debt
Current: No Debt

Equity to Asset 0.56
CDXS's Equity to Asset is ranked higher than
66% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CDXS: 0.56 )
CDXS' s 10-Year Equity to Asset Range
Min: -1.82   Max: 0.79
Current: 0.56

-1.82
0.79
F-Score: 4
Z-Score: -6.62
M-Score: -4.81
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -95.99
CDXS's Operating margin (%) is ranked higher than
72% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. CDXS: -95.99 )
CDXS' s 10-Year Operating margin (%) Range
Min: -155.16   Max: -6.65
Current: -95.99

-155.16
-6.65
Net-margin (%) -95.40
CDXS's Net-margin (%) is ranked higher than
72% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. CDXS: -95.40 )
CDXS' s 10-Year Net-margin (%) Range
Min: -153.96   Max: -7.97
Current: -95.4

-153.96
-7.97
ROE (%) -79.66
CDXS's ROE (%) is ranked higher than
62% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. CDXS: -79.66 )
CDXS' s 10-Year ROE (%) Range
Min: -68.88   Max: -11.85
Current: -79.66

-68.88
-11.85
ROA (%) -53.88
CDXS's ROA (%) is ranked higher than
63% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. CDXS: -53.88 )
CDXS' s 10-Year ROA (%) Range
Min: -52.02   Max: -7.11
Current: -53.88

-52.02
-7.11
ROC (Joel Greenblatt) (%) -378.27
CDXS's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. CDXS: -378.27 )
CDXS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -690.93   Max: -33.11
Current: -378.27

-690.93
-33.11
Revenue Growth (%) -42.40
CDXS's Revenue Growth (%) is ranked higher than
61% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. CDXS: -42.40 )
CDXS' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -42.4
Current: -42.4

EPS Growth (%) 45.60
CDXS's EPS Growth (%) is ranked higher than
96% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. CDXS: 45.60 )
CDXS' s 10-Year EPS Growth (%) Range
Min: 0   Max: 45.6
Current: 45.6

0
45.6
» CDXS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CDXS Guru Trades in Q4 2013

Jim Simons 246,943 sh (+193.63%)
» More
Q1 2014

CDXS Guru Trades in Q1 2014

Jim Simons 196,292 sh (-20.51%)
» More
Q2 2014

CDXS Guru Trades in Q2 2014

Jim Simons 209,000 sh (+6.47%)
» More
Q3 2014

CDXS Guru Trades in Q3 2014

Jim Simons 281,800 sh (+34.83%)
» More
» Details

Insider Trades

Latest Guru Trades with CDXS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2011-12-31 Sold Out 0.0012%$4.24 - $6.02 $ 2.59-2%0
George Soros 2011-09-30 New Buy$4.39 - $10.24 $ 2.59-63%14800
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.92
CDXS's P/B is ranked higher than
81% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. CDXS: 3.92 )
CDXS' s 10-Year P/B Range
Min: 0.83   Max: 4.19
Current: 3.92

0.83
4.19
P/S 3.22
CDXS's P/S is ranked higher than
93% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. CDXS: 3.22 )
CDXS' s 10-Year P/S Range
Min: 0.27   Max: 3.68
Current: 3.22

0.27
3.68
EV-to-EBIT -2.65
CDXS's EV-to-EBIT is ranked higher than
60% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CDXS: -2.65 )
CDXS' s 10-Year EV-to-EBIT Range
Min: -42   Max: -0.4
Current: -2.65

-42
-0.4
Current Ratio 2.56
CDXS's Current Ratio is ranked higher than
63% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. CDXS: 2.56 )
CDXS' s 10-Year Current Ratio Range
Min: 1.14   Max: 3.98
Current: 2.56

1.14
3.98
Quick Ratio 2.39
CDXS's Quick Ratio is ranked higher than
64% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. CDXS: 2.39 )
CDXS' s 10-Year Quick Ratio Range
Min: 1.07   Max: 3.75
Current: 2.39

1.07
3.75

Valuation & Return

vs
industry
vs
history
Price/Net Cash 51.80
CDXS's Price/Net Cash is ranked higher than
74% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. CDXS: 51.80 )
CDXS' s 10-Year Price/Net Cash Range
Min: 3.45   Max: 42.2
Current: 51.8

3.45
42.2
Price/Net Current Asset Value 19.90
CDXS's Price/Net Current Asset Value is ranked higher than
76% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. CDXS: 19.90 )
CDXS' s 10-Year Price/Net Current Asset Value Range
Min: 2.76   Max: 16.23
Current: 19.9

2.76
16.23
Price/Tangible Book 6.80
CDXS's Price/Tangible Book is ranked higher than
78% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. CDXS: 6.80 )
CDXS' s 10-Year Price/Tangible Book Range
Min: 1.34   Max: 5.55
Current: 6.8

1.34
5.55
Price/Median PS Value 2.30
CDXS's Price/Median PS Value is ranked higher than
74% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. CDXS: 2.30 )
CDXS' s 10-Year Price/Median PS Value Range
Min: 0.22   Max: 2.31
Current: 2.3

0.22
2.31
Earnings Yield (Greenblatt) -37.70
CDXS's Earnings Yield (Greenblatt) is ranked higher than
52% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. CDXS: -37.70 )
CDXS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -37.7   Max: 0
Current: -37.7

-37.7
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:4QK.Germany,
Codexis, Inc. was incorporated in Delaware in January 2002. The Company is a developer of proprietary biocatalysts, which are enzymes or microbes that initiate or accelerate chemical reactions. Its proven technologies enable scale-up and implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable process development, from research to manufacturing. The Company has commercialized its technology and products in the pharmaceuticals market. The pharmaceutical customers, which include several pharmaceutical companies, use its technology, products and services in their manufacturing process development, including in the production of some of the world's bestselling and fastest growing drugs. It has recently started to use its technology to develop biocatalysts for use in the fine chemicals markets. The fine chemicals market is similar to its pharmaceutical business and consists of several large market segments, including food, animal feed, polymers, flavors and fragrances and agricultural chemicals, and so it is a natural fit for its technology. Its technology is also currently being used by a customer to manufacture butadiene, an intermediate for the manufacture of polymers. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (API), and Codex Biocatalyst Kits and Panels. It markets and sells enzymes, development services and Codex Biocatalyst Kits and Panels screening tools that enable novel manufacturing processes for APIs and their precursor pharmaceutical intermediates. It also markets and sells pharmaceutical intermediates that are manufactured using its custom enzymes. The registered and pending United States and foreign trademarks include Codexis, Codex, CodeEvolver, CodeXporter, CodeXol, CodeXyme, Powered by CodeEvolver, We Are Biocatalysis, Mosaic, Sage, Microcyp, Hit from a Kit, Prosar and a Codexis and design mark. The competitors include Solvias Inc. and Takasago International Corporation who use metal-based chemical reactions for their pharmaceutical products, industrial enzyme companies, such as Novozymes, as well as subsidiaries of larger pharmaceutical companies, such as DSM, Cambrex Corporation and Almac Group Ltd. There is also competition in the customized and optimized enzyme area from several small European companies, such as BRAIN AG, C-LEcta GmbH and evocatal GmbH. The Company's operations comply with environmental laws and regulations.
» More Articles for CDXS

Headlines

Articles On GuruFocus.com
Weekly 3-Year Lows Highlight: SEAS, AMTG, AHH, NCTY, CDXS Dec 30 2013 
comment on CDXS Mar 23 2013 
Weekly CEO Buys Highlight: AKAM, DRC, MDRX, MTG, CDXS Mar 17 2013 
A New Beginning for Codexis? Mar 08 2013 
Weekly CFO Buys Highlight: ASNB, FXCM, CDXS, VTNC, BRS Sep 24 2012 

More From Other Websites
Codexis Uses Its CodeEvolver(R) Protein Engineering Platform Technology to Develop an Enzyme... Dec 03 2014
Codexis Uses Its CodeEvolver(R) Protein Engineering Platform Technology to Develop an Enzyme... Dec 03 2014
Codexis to Present at the LD Micro Main Event VII Conference on December 4 Nov 25 2014
Codexis to Present at the LD Micro Main Event VII Conference on December 4 Nov 25 2014
Insider Trading Alert - ITG, CDXS And ARQL Traded By Insiders Nov 21 2014
CODEXIS INC Financials Nov 15 2014
10-Q for Codexis, Inc. Nov 08 2014
CODEXIS INC Files SEC form 8-K, Change in Directors or Principal Officers Nov 07 2014
CODEXIS INC Files SEC form 10-Q, Quarterly Report Nov 06 2014
Codexis Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2014 Nov 04 2014
CODEXIS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 04 2014
Codexis Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2014 Nov 04 2014
Codexis Appoints Pam P. Cheng, Merck Global Executive, to Board of Directors Nov 03 2014
CODEXIS INC Files SEC form 8-K, Change in Directors or Principal Officers Nov 03 2014
Codexis Appoints Pam P. Cheng, Merck Global Executive, to Board of Directors Nov 03 2014
Codexis to Report Third Quarter 2014 Financial Results on November 4 Oct 21 2014
Codexis to Report Third Quarter 2014 Financial Results on November 4 Oct 21 2014
CODEXIS INC Files SEC form 8-K, Change in Directors or Principal Officers Sep 22 2014
Codexis Appoints Biotechnology Industry Veteran, Kathleen Glaub, to Board of Directors Sep 22 2014
CODEXIS INC Files SEC form 10-Q, Quarterly Report Aug 08 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK